Ghost Tree Capital, LLC Fate Therapeutics Inc Transaction History

Ghost Tree Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 16, 2022	SELL	$47.84 - $64.34 $2.39 Million - $3.22 Million	-50,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $8 Million - $12.9 Million	-135,000 Reduced 72.97%	50,000 $2.96 Million
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $1.44 Million - $2.35 Million	20,000 Added 12.12%	185,000 $15.3 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $1.33 Million - $3.53 Million	-35,000 Reduced 17.5%	165,000 $15 Million
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $2.28 Million - $3.04 Million	75,000 Added 60.0%	200,000 $7.99 Million
Q2 2020 Aug 14, 2020	SELL	$20.21 - $35.23 $2.02 Million - $3.52 Million	-100,000 Reduced 44.44%	125,000 $4.29 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $864,000 - $1.59 Million	-50,000 Reduced 18.18%	225,000 $5 Million
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $1 Million - $1.55 Million	-75,000 Reduced 21.43%	275,000 $5.38 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $5.41 Million - $7.88 Million	350,000 New	350,000 $5.44 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $861,000 - $1.27 Million	-75,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $656,250 - $1.22 Million	75,000 New	75,000 $1.22 Million

190

123M

15K

14K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $346M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.